Global hypomethylation of peripheral leukocyte DNA in male patients with schizophrenia: A potential link between epigenetics and schizophrenia

Shimabukuro, M.; Sasaki, Tsukasa; Imamura, Akira; Tsujita, Takahiro; Fuke, Chiaki; Umekage, Tadashi; Tochigi, Mamoru; Hiramatsu, Kennichi; Miyazaki, Tetsuji; Oda, Takaya; Sugimoto, Jun; Jinno, Yoshihiro; Okazaki, Yuji

doi:10.1016/j.jpsychires.2006.08.006

Cited by 101 publications

(71 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, it is not suprising that studies have evaluated the global methylation pattern in people with Sz [117120] . Overall, leukocyte DNA from people with Sz had lower methylated deoxycytidine (mC) content compared to controls [120] . In addition, a genome wide study showed there were 234 CpG sites (0.04% of CpG sites) that were differentially methylated in both people with Sz who were drugnaïve compared to controls and in people with Sz compared to their discordant monozygotic twin sibling [118] , with most of the sites located in promoter regions of genes.…”

Section: Epigenetics and Micrornamentioning

confidence: 99%

Biomarkers in schizophrenia: A focus on blood based diagnostics and theranostics

Lai

Scarr

Udawela

et al. 2016

WJP

140

108

View full text Add to dashboard Cite

Identifying biomarkers that can be used as diagnostics or predictors of treatment response (theranostics) in people with schizophrenia (Sz) will be an important step towards being able to provide personalized treatment. Findings from the studies in brain tissue have not yet been translated into biomarkers that are practical in clinical use because brain biopsies are not acceptable and neuroimaging techniques are expensive and the results are inconclusive. Thus, in recent years, there has been search for blood-based biomarkers for Sz as a valid alternative. Although there are some encouraging preliminary data to support the notion of peripheral biomarkers for Sz, it must be acknowledged that Sz is a complex and heterogeneous disorder which needs to be further dissected into subtype using biological based and clinical markers. The scope of this review is to critically examine published blood-based biomarker of Sz, focusing on possible uses for diagnosis, treatment response, or their relationship with schizophreniaassociated phenotype. We sorted the studies into six categories which include: (1) brain-derived neurotrophic factor; (2) inflammation and immune function; (3) neurochemistry; (4) oxidative stress response and metabolism; (5) epigenetics and microRNA; and (6) transcriptome and proteome studies. This review also summarized the molecules which have been conclusively reported as potential blood-based biomarkers for Sz in different blood cell types. Finally, we further discusses the pitfall of current blood-based studies and suggest that a prediction model-based, Sz specific, blood World Journal of Psychiatry W J P oriented study design as well as standardize blood collection conditions would be useful for Sz biomarker development.

show abstract

Section: Epigenetics and Micrornamentioning

confidence: 99%

Biomarkers in schizophrenia: A focus on blood based diagnostics and theranostics

Lai

Scarr

Udawela

et al. 2016

WJP

140

108

View full text Add to dashboard Cite

show abstract

“…However, global hypomethylation is subject to a high degree of variability, unaccounted for by our current level of understanding (10,11). In addition to neoplastic transformation, problems of epigenetic regulation, including CpG methylation disorders are also involved in a wide range of pathological phenomena (12,13). In most eukaryotes, methylation of DNA occurs at the cytosine residues of cytosine-phospho-guanine (CpG) dinucleotides.…”

Section: U N C O R R E C T E D P R O O Fmentioning

confidence: 99%

Flow Cytometric and Laser Scanning Microscopic Approaches in Epigenetics Research

Székvölgyi

Imre

Minh

et al. 2009

Chromatin Immunoprecipitation Assays

View full text Add to dashboard Cite

Our understanding of epigenetics has been transformed in recent years by the advance of technological possibilities based primarily on a powerful tool, chromatin immunoprecipitation (ChIP). However, in many cases, the detection of epigenetic changes requires methods providing a high-throughput (HTP) platform. Cytometry has opened a novel approach for the quantitative measurement of molecules, including PCR products, anchored to appropriately addressed microbeads (Pataki et al. 2005. Cytometry 68, 45-52). Here we show selected examples for the utility of two different cytometry-based platforms of epigenetic analysis: ChIP-on-beads, a flow-cytometric test of local histone modifications (Balint et al. 2005. Mol. Cell Biol. 25, 5648-5663), and the laser scanning cytometry-based measurement of global epigenetic modifications that might help predict clinical behavior in different pathological conditions. We anticipate that such alternative tools may shortly become indispensable in clinical practice, translating the systematic screening of epigenetic tags from basic research into routine diagnostics of HTP demand.

show abstract

“…Studies on WBC DNA methylation and other disease points are more limited but are starting to emerge with respect to Alzheimers's disease, schizophrenia and myelodysplastic syndrome. [30][31][32] …”

mentioning

confidence: 99%

DNA methylation in white blood cells

et al. 2011

View full text Add to dashboard Cite

Global hypomethylation of peripheral leukocyte DNA in male patients with schizophrenia: A potential link between epigenetics and schizophrenia

Cited by 101 publications

References 37 publications

Biomarkers in schizophrenia: A focus on blood based diagnostics and theranostics

Biomarkers in schizophrenia: A focus on blood based diagnostics and theranostics

Flow Cytometric and Laser Scanning Microscopic Approaches in Epigenetics Research

DNA methylation in white blood cells

Contact Info

Product

Resources

About